argenx NV ADR (ARGX)
argenx NV ADR (ARGX) carries a ŷRobot AI score of 62 out of 100. The model's fair value estimate is $922.98, 3.9% below the last close of $960.04. The chart signal reads Hold.
| Metric | ARGX |
|---|---|
| AI score | 62 / 100 |
| Chart signal | Hold |
| Fair value estimate | $922.98 |
| Upside to fair value | -3.9% |
| Previous close | $960.04 |
| P/E | 30.26 |
| Price / sales | 9.24 |
| Market cap | $61.10B |
| EPS | 28.87 |
| Revenue growth | 61.1% |
| 1-year price change | 22.6% |
How these numbers are built: the AI score, the fair value model, and the chart signal.
Other Healthcare stocks: Eli Lilly and Company, Johnson & Johnson, AbbVie Inc, Merck & Company Inc, UnitedHealth Group Incorporated, Novartis AG ADR.
Questions about ARGX
Is ARGX overvalued or undervalued right now?
As of Oct 26, 2026, ŷRobot's fair-value model estimates argenx NV ADR (ARGX) at $922.98 against a last close of $960.04, implying 3.9% downside to the model's estimate.
Is ARGX's chart signal bullish or bearish?
The chart-signal model classifies ARGX as Neutral as of Nov 13, 2026, with a signal score of -0.02 on a -1 to 1 scale.
What is ARGX's ŷRobot AI score?
ARGX scores 62 out of 100 on ŷRobot's AI composite, which measures how strongly the fair-value and chart models agree, as of Nov 13, 2026.
Is ARGX stock expensive on P/E and P/S?
ARGX trades at 30.3 times earnings and 9.2 times sales as of Nov 13, 2026.
What does ARGX's seasonal forecast show?
ŷRobot's seasonal forecast curve for ARGX reads +5.7% at 30 days, +9.6% at 90 days, and +22.6% at one year as of Nov 13, 2026. Seasonal tendencies are historical patterns, not predictions.
How fast is ARGX growing?
argenx NV ADR's revenue growth is +61.1% and free-cash-flow growth is +1.6% on the latest reported figures.
ARGX chart and technical read · All covered stocks
ŷRobot analysis is AI-generated and quality-gated; nothing here is investment advice.